Author/Creator: Lalezari, Shadan - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Lalezari, Shadan

1. BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years. (23rd March 2020)

Authors:: Mahlangu, Johnny; Lopez Fernandez, Maria Fernanda; Santagostino, Elena; Lalezari, Shadan; Tseneklidou‐Stoeter, Despina; Beckmann, Horst; Church, Nikki
Journal:: European journal of haematology
Issue:: Volume 104:Number 6(2020)
Page Start:: 594
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Issue 6 (17th October 2019)

Authors:: Lalezari, Shadan; Reding, Mark T.; Pabinger, Ingrid; Holme, Pal Andre; Negrier, Claude; Chalasani, Pavani; Shin, Ho‐Jin; Wang, Maria; Tseneklidou‐Stoeter, Despina; Maas Enriquez, Monika
Journal:: Haemophilia
Issue:: Volume 25:Issue 6(2019)
Page Start:: 1011
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Issue 3 (5th April 2021)

Authors:: Reding, Mark T.; Pabinger, Ingrid; Holme, Pal Andre; Poulsen, Lone; Negrier, Claude; Chalasani, Pavani; Maas Enriquez, Monika; Wang, Maria; Meijer, Karina; Mancuso, Maria Elisa; Lalezari, Shadan
Journal:: Haemophilia
Issue:: Volume 27:Issue 3(2021)
Page Start:: e347
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection. Issue 3 (16th April 2020)

Authors:: Solms, Alexander; Lalezari, Shadan; Shah, Anita; Kenet, Gili
Journal:: Haemophilia
Issue:: Volume 26:Issue 3(2020)
Page Start:: e145
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Issue 183 (November 2019)

Authors:: Santagostino, Elena; Lalezari, Shadan; Reding, Mark T.; Ducore, Jonathan; Ng, Heng Joo; Poulsen, Lone H.; Michaels, Lisa A.; Linardi, Camila C.G.
Journal:: Thrombosis research
Issue:: Issue 183(2019)
Page Start:: 13
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A. Issue 4 (3rd May 2021)

Authors:: Santagostino, Elena; Lalezari, Shadan; Reding, Mark T.; Ducore, Jonathan; Ng, Heng Joo; Poulsen, Lone H.; Michaels, Lisa A.; Linardi, Camila
Journal:: Haemophilia
Issue:: Volume 27:Issue 4(2021)
Page Start:: e559
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027. Issue 4 (23rd June 2020)

Authors:: Reding, Mark T.; Pabinger, Ingrid; Lalezari, Shadan; Santagostino, Elena; Mancuso, Maria Elisa
Journal:: Haemophilia
Issue:: Volume 26:Issue 4(2020)
Page Start:: e201
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗